newsfilter
← Latest News
GlobeNewswire·

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased